Revolution Medicines Sets Rasonque at $480,000 a Year as Cancer Drug Prices Normalize
Updated
Updated · The New York Times · Aug 31
Revolution Medicines Sets Rasonque at $480,000 a Year as Cancer Drug Prices Normalize
1 articles · Updated · The New York Times · Aug 31
Summary
$480,000 a year is the sticker price Revolution Medicines set for Rasonque, its new pancreatic cancer pill, or about $663 per tablet.
Revolution said the price reflects Rasonque's differentiation and meaningful patient benefit, but the launch fits a broader market where companies face few limits beyond what buyers will bear.
Nine cancer drugs approved in 2024 debuted above $400,000 annually, according to the Institute for Clinical and Economic Review, underscoring how sharply pricing has climbed from the era when $100,000-a-year therapies drew fierce backlash.
$600,000 CAR-T infusions, a $550,000 rival therapy and pills priced at $520,000 and $430,000 a year show the burden now falls routinely on Medicare, employers, patients and taxpayers.